Skip to main content

Table 3 Significant serum metabolites identified between HCs and the IT phase

From: Metabolic characterization of the natural progression of chronic hepatitis B

Targeted metabolomics platform

Class

Metabolite species identified as significant between the HCs and IT phase

Trend in the IT phase

Phospholipids

Positive lipids

Phosphatidylcholines (PC)

C32:1, C32:2, C34:1, C34:3, C34:4, C36:3, C36:4, C36:6, C38:3

Decreased

Phosphatidylethanolamines (PE)

C38:4

Decreased

Plasmalogens

Positive lipids

Plasmalogen phosphatidylcholines (pPC)

C34:2, C36:2, C36:3, C38:6

Increased

Plasmalogen phosphatidylethanolamines (PE)

C38:5, C38:7#

Increased

Lysophospholipids

Negative lipids

Lysophosphatidylcholines (LPC)

sn1: C14:0, C15:0, C16:1, C18:1, C18:2, C18:3 (ω3ω6), C20:3 (ω3ω6), C20:3 (ω9), C20:4, C22:4, C22:5 (ω6)

Decreased

sn2: C14:0, C16:1, C18:1, C18:2, C18:3 (ω3ω6), C20:3 (ω3ω6), C20:4

Lysophosphatidylethanolamines (LPE)

C18:0, C18:1, C18:2#, C20:3 (ω3ω6), C20:4, C22:5# (ω3)

Decreased

Plasmalogen lysophospholipids

Negative lipids

Plasmalogen lysophosphatidylcholines (pLPC)

C16:0, C16:1, C18:1, C18:2

Increased

Triglycerides

Positive lipids

Triglycerides

C42:1, C44:2, C46:1, C46:2, C46:3, C48:1, C48:2, C48:3, C48:4#, C50:0, C50:1, C50:2, C50:3, C50:4, C50:5, C51:1, C51:2, C51:3, C52:1, C52:2, C54:1, C54:2, C55:2, C56:5, C58:5

Decreased

Amines

Biogenic amines

Amino acids

Tryptophan#

Decreased

Glutathione

Glutathione

Decreased

Dipeptides

γ-Glutamylglutamine

Decreased

Amino acids metabolites

Kynurenine, saccharopine

Decreased

Hepatic injury

4-Hydroxyproline, pipecolic acid

Increased

Glycine metabolism

Betaine#, sarcosine#

Increased

Other

s-Methylcysteine

Increased

Sphingomyelins

Positive lipids

Sphingomyelins (SM)

C18:1/14:0, C18:1/21:0, C18:1/23:0, C18:1/25:0, C18:1/25:1

Decreased

Free fatty acids and Acyl-carnitines

Negative lipids

Free fatty acids (FFA)

C18:2, C20:2

Increased

Acyl-carnitines

Acyl-carnitines

Oleylcarnitine (C18:1)#, Linoleylcarnitine (C18:2)

Increased

Nonanoylcarnitine (C9:0)

Decreased

Others

Positive lipids

Cholestrol esters (CE)

C18:3

Decreased

Oxylipins

Oxylipins

11-HDoHE#, 14-HDoHE#, 10-HDoHE#

Increased

5-HETrE, 8,9-DiHETre,#, 12,13-DiHOME,#

Decreased

  1. The metabolites identified as significant based on t-test and fold change are divided into their different classes together with their trend. All metabolites had a q value <0.05 unless otherwise indicated
  2. # q value >0.05